Emilio Clementi

InstitutionE. Medea Scientific Institute
AddressItaly
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 8 Covid-19 publications, with a maximum of 2 publications in June 2020
    All Publications
    Bar chart showing 328 publications over 28 distinct years, with a maximum of 38 publications in 2014
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gringeri M, Mosini G, Battini V, Cammarata G, Guarnieri G, Carnovale C, Clementi E, Radice S. Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility. Hum Vaccin Immunother. 2021 09 02; 17(9):2969-2971. PMID: 34043934.
      Citations: 5     Fields:    Translation:Humans
    2. Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G, Giorgi V, Invernizzi A, Maconi G, Maier JA, Marzano AV, Morpurgo PS, Nebuloni M, Radovanovic D, Riva A, Rizzardini G, Sabiu G, Santus P, Staurenghi G, Zuccotti G, Sarzi-Puttini PC, Ardizzone S. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Front Immunol. 2021; 12:656362. PMID: 33936084.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    3. Zanon D, Musazzi UM, Manca A, De Nicolò A, D'Avolio A, Cilurzo F, Maximova N, Tomasello C, Clementi E, Minghetti P. Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. Data Brief. 2020 Dec; 33:106445. PMID: 33110933.
      Citations: 1     
    4. Baldelli S, Corbellino M, Clementi E, Cattaneo D, Gervasoni C. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020 09 01; 75(9):2704-2706. PMID: 32407513.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    5. Cismaru AC, Cismaru LG, Nabavi SF, Berindan-Neagoe I, Clementi E, Banach M, Nabavi SM. Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series? Arch Med Sci. 2021; 17(2):275-284. PMID: 33747262.
      Citations: 1     
    6. Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, Los MJ, Clementi E, Nabavi SM, Ghavami S. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Eur J Pharmacol. 2020 Sep 05; 882:173288. PMID: 32561291.
      Citations: 25     Fields:    Translation:HumansCellsPHPublic Health
    7. Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, Gervasoni C, Clementi E, Clementi E. Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020 08; 158:104898. PMID: 32438034.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    8. Nabavi SF, Habtemariam S, Clementi E, Berindan-Neagoe I, Cismaru CA, Rasekhian M, Banach M, Izadi M, Bagheri M, Bagheri MS, Nabavi SM. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch Med Sci. 2020; 16(3):519-521. PMID: 32399097.
      Citations: 7